Skip to Content

Imagify Approval Status

Imagify (perflubutane) is an investigational imaging agent intended to assess perfusion using ultrasound (or echocardiography) for the detection of coronary artery disease.

In February 2009, Acusphere Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for Imagify had not been approved.

Development Status and FDA Approval Process for Imagify

Feb 18, 2009Acusphere Announces Change In Imagify Regulatory Strategy and Deferral of Near-Term Contractual Cash Payments
Dec 11, 2008Acusphere Announces Results of FDA Advisory Committee Meeting
Dec  8, 2008Acusphere, Inc. Announces Posting of Briefing Documents for FDA Cardio Renal Drugs Advisory Committee Meeting on Imagify
Oct 13, 2008Acusphere's Imagify to be Reviewed at FDA Advisory Committee Meeting on December 10, 2008
Jun 30, 2008Acusphere Announces FDA Acceptance of Imagify NDA for Detection of Coronary Artery Disease
Apr 29, 2008Acusphere Submits New Drug Application for FDA Approval of Imagify

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.